Current treatment status-Undergoing active treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Posted by on Sep 16, 2021 in Leukemia | 0 comments

In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...

Read More

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Evaluating dual-target CAR T-cell therapy for patients with unresponsive B-cell NHL

Posted by on Aug 8, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of dual chimeric antigen receptor (CAR) T-cell therapy for patients with recurrent or hard-to-treat B-cell non-Hodgkin lymphoma (NHL). This study found that this treatment was safe and effective for these patients. Some background B-cell non-Hodgkin’s lymphoma (NHL) is one of...

Read More

Does tyrosine kinase inhibitors dose reduction influence the outcomes of patients with in chronic myeloid leukemia?

Does tyrosine kinase inhibitors dose reduction influence the outcomes of patients with in chronic myeloid leukemia?

Posted by on Jan 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effect of tyrosine kinase inhibitor (TKI) dose reduction in patients with chronic myeloid leukemia (CML) after achieving a major molecular response (MMR).   This study concluded that the TKI dose reduction was safe and effective for the majority of these...

Read More

Evaluating cachexia after first-line treatment for patients with colorectal cancer

Evaluating cachexia after first-line treatment for patients with colorectal cancer

Posted by on Dec 5, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the occurrence of cachexia (CX; weight loss and muscle wasting) in patients with advanced colorectal cancer after first-line therapy. Researchers suggested that CX is present in half of these patients within 24 weeks after starting first-line therapy. Some background Colorectal cancer is the third most common...

Read More

Can tumor DNA in the blood predict how well patients with melanoma will respond to immune therapy?

Can tumor DNA in the blood predict how well patients with melanoma will respond to immune therapy?

Posted by on Nov 13, 2020 in Melanoma | 0 comments

In a nutshell This study looked at the role of circulating tumor DNA (ctDNA) in predicting treatment response in advanced melanoma. They found that in patients treated for the first time with immune treatment, patients with low ctDNA levels had a longer survival without cancer worsening. Some background Advanced melanoma describes melanoma...

Read More

Anti-PD1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma

Anti-PD1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma

Posted by on Oct 18, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated outcomes of anti-programmed cell death-1 monoclonal antibodies (anti-PD-1-mAbs or APMs) before and after allogeneic hematopoietic cell transplantation (alloHCT) for patients with relapsed/refractory Hodgkin lymphoma (r/r-HL). The authors found that patients receiving APMs before alloHCT had frequent immune-related...

Read More

Benefits of autologous hematopoietic stem cell transplantation after checkpoint inhibitor therapy in patients with relapsed/refractory Hodgkin lymphoma

Benefits of autologous hematopoietic stem cell transplantation after checkpoint inhibitor therapy in patients with relapsed/refractory Hodgkin lymphoma

Posted by on Oct 3, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated real-life benefits of autologous hematopoietic stem cell transplantation (ASCT) after immune checkpoint inhibitor (CPi) therapy in patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL). The authors found that ASCT can be an effective option after CPi therapy in such patients. Some background Some patients...

Read More

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Posted by on Jun 28, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...

Read More

Evaluating the effects of chemotherapy on cognitive function in patients with early breast cancer

Evaluating the effects of chemotherapy on cognitive function in patients with early breast cancer

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Colorectal cancer | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More